This article explores the potential risks of using Semaglutide (Ozempic®) during pregnancy and breastfeeding. Animal studies indicate possible fetal development issues and pregnancy loss. Women planning conception should consult healthcare providers to ensure safety. The article emphasizes the importance of managing diabetes carefully during pregnancy to prevent complications. While Semaglutide’s presence in animal milk shows low risk for humans, professional medical guidance is essential for safe medication use during pregnancy and lactation.

Potential Dangers of Semaglutide Use During Pregnancy

Semaglutide, marketed as Ozempic®, is a medication designed to simulate the glucagon hormone, aiding blood sugar regulation and digestion. Administered through a single-use injection pen, it is mainly used to control type 2 diabetes in individuals with inadequate insulin response. It is not recommended for treating type 1 diabetes and is typically prescribed only after other treatments have failed to achieve desired blood sugar levels.

Medications contain chemical compounds that can interact with the body, especially during critical periods like pregnancy. Certain drugs should be avoided to prevent harmful effects on both mother and fetus. This article discusses the potential risks associated with using Semaglutide during pregnancy and breastfeeding.

Pregnancy
Limited research exists on Semaglutide safety during pregnancy due to a lack of comprehensive studies. Animal experiments suggest possible risks, such as fetal malformations and pregnancy loss, particularly when taken during fetal organ development phases.

Studies involving pregnant rats, rabbits, and monkeys reveal potential hazards of Semaglutide. In pregnant rats, low doses caused abnormal fetal development and slowed growth. Rabbits and primates experienced early pregnancy terminations and skeletal issues. Women intending to conceive should discontinue use at least two months before pregnancy, considering the drug’s prolonged half-life.

Medical Guidance — Proper management of diabetes during pregnancy is essential. High blood sugar levels can lead to complications like ketoacidosis, miscarriage, preterm delivery, or pre-eclampsia. The fetus faces risks of birth defects, abnormal growth, and health problems.

Research Insights — Animal studies show the effects of Semaglutide at various doses. In one study, doses resembling 0.01, 0.03, and 0.09 mg/kg/day caused weight loss and developmental disturbances in rats. Similar findings in pregnant monkeys and rabbits included weight reduction, decreased food intake, and fetal anomalies.

Semaglutide was detected in rat milk; however, due to species differences, it's unlikely to affect human breastfed infants. Nonetheless, breastfeeding decisions should involve careful consideration of risks and benefits, with guidance from healthcare professionals.

Important Reminder:

This content is for educational purposes and does not substitute professional medical advice. Consult healthcare providers for personalized diagnosis and treatment options.